Harnessing the immune system to target cancer is the goal of a groundbreaking area of oncology research called cell therapy. And Johnson & Johnson is hard at work in the cutting-edge field, aiming to deliver potential newtreatment options to people around the world.
From robotics solutions for orthopedic surgery to the potential to bring new hope to patients living with multiple myeloma through CAR-T, these are just some of the cutting-edge projects that these visionaries think could potentially help propel healthcare forward around the globe.
From a $10 million pledge to UNICEF in support of health workers to promising news about a preventive HIV vaccine regimen, the company’s new 2018 Health for Humanity Report details how Johnson & Johnson is dedicated to creating a better future for everyone, everywhere.
Brad Heidrich’s diagnosis with a deadly cancer at age 13 changed the course of his life—and inspired the person he would become: a Janssen scientist dedicated to working on therapies for blood cancer. For Blood Cancer Awareness Month, we share his incredible story.
Hundreds of millions of people worldwide have type 2 diabetes. And Chiara Magnone has her sights set on changing what it means to live with the condition, as well as how common complications like chronic kidney disease are treated.
Johnson & Johnson and Chinese company Legend Biotech have teamed up to work on a new form of treatment for the incurable blood cancer. We interview Dr. Sen Zhuang about the unique collaboration—and the promise it holds.
It's been in the news, but what does CAR-T really mean for patients? Immuno-oncology expert Iqbal Grewal, Ph.D., explains why the treatment has the potential to be a game changer for people with all types of cancer down the road.